Ads
related to: Vertex
Search results
Vertex Pharmaceuticals (NASDAQ:VRTX) Downgraded by StockNews.com
ETF DAILY NEWS· 1 day agoBarclays lifted their target price on Vertex Pharmaceuticals from $446.00 to $472.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. Wolfe ...
Vertex Pharmaceuticals Q1 2024 Earnings: Surpasses Revenue Expectations with Strategic Expansions
GuruFocus.com via Yahoo Finance· 6 days agoStrategic Acquisition: Announced the acquisition of Alpine Immune Sciences, enhancing the pipeline...
Vertex, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Simply Wall St. via Yahoo Finance· 23 hours agoIt's been a good week for Vertex, Inc. (NASDAQ:VERX) shareholders, because the company has just...
Vertex's (VRTX) Q1 Earnings Beat, Trikafta Drives Sales
Zacks via Yahoo Finance· 5 days agoVertex's (VRTX) first-quarter earnings and revenues surpass estimates. Higher sales of...
Decoding Vertex Pharmaceuticals Inc (VRTX): A Strategic SWOT Insight
GuruFocus.com via Yahoo Finance· 3 days agoVertex Pharmaceuticals Inc (NASDAQ:VRTX) showcases robust revenue growth and solid operational...
Earnings call: Vertex Energy pivots from renewables to conventional fuels By Investing.com
Investing.com· 2 days agoVertex Energy (NASDAQ:VTNR) has announced a strategic shift away from renewable diesel production...
Vertex's Pain Drug Could Be Worth Up To $11.4 Billion — Ongoing Debate Sparks Shares
Investor's Business Daily· 5 days agoVertex stock advanced Tuesday as analysts debated the company's pain drug, VX-548, with one saying...
Vertex shares eise on earnings beat
Investing.com· 6 days agoVertex Pharmaceuticals (NASDAQ: VRTX ) Incorporated ( NASDAQ : VRTX) reported a robust first quarter for 2024, surpassing analyst expectations with a 13%...
Earnings call: Vertex Pharmaceuticals reports solid Q1 growth, plans expansion By Investing.com
Investing.com· 5 days agoVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has reported a robust 13% year-over-year revenue...
5 Reasons Vertex Pharmaceuticals Is a Screaming Buy on the Dip
Motley Fool via Yahoo Finance· 4 days agoShares of Vertex Pharmaceuticals (NASDAQ: VRTX) are down about 8% from a peak they reached this...
